Archives
-
AM 281 and the CB1–CREB–GLT-1 Axis
2026-10-05
Recent mouse traumatic brain injury research positions CB1 signaling as a potential regulator of astrocytic GLT-1 and glutamate-related cognitive dysfunction. This thought-leadership article interprets how AM 281 can support mechanistic CB1 cannabinoid receptor antagonist research while distinguishing reported findings from translational hypotheses, product claims, and evidence limitations.
-
Pronase E in Ferroptosis Evidence Analysis
2026-10-05
Pronase E is a broad-spectrum protease mixture with a distinctive role in ferroptosis research: not as proof of mechanism, but as an analytical reagent for examining protein evidence. This article separates sample-preparation utility from causal interpretation in a recent gramine study of the CUL3–MTDH axis.
-
C8-HSL in Microbial Signaling and Lung Cancer
2026-10-04
N-octanoyl-L-Homoserine lactone, or C8-HSL, is a quorum-sensing molecule associated with Gram-negative bacterial communication. A 2026 FASEB Journal study reports that C8-HSL promoted proliferation, migration, and invasion in H460 lung cancer cells through PI3K/AKT/ERK-associated signaling, while important questions about exposure, specificity, clinical relevance, and validation remain unresolved.
-
How Near-Death Cells Acquire Metastatic States
2026-10-03
Conod, Silvano, and Ruiz i Altaba report that tumor cells surviving impending death can acquire stable prometastatic properties rather than merely represent a pre-existing aggressive subpopulation. Their Cell Reports study links this transition to ER stress, PERK–CHOP signaling, GLI and NANOG-associated reprogramming, and cytokine-mediated recruitment of neighboring cells, providing a framework for understanding how metastatic ecosystems may emerge after cytotoxic stress.
-
AG-221 (Enasidenib): From 2-HG to AML Strategy
2026-10-02
AG-221 (Enasidenib) is more than an IDH2 inhibitor: it is a translational tool for connecting oncometabolite suppression, leukemia cell differentiation, and metabolic dependencies. This article interprets recent CD44 findings and outlines a practical strategy for designing mechanistically informative IDH2-mutant AML studies.
-
Reactive Oxygen Species Assay Kit in Nanomedicine
2026-10-01
Discover how the Reactive Oxygen Species Assay Kit and DCFH-DA fluorescent probe can map redox responses in live-cell nanomedicine experiments. This guide connects ROS measurement with ROS-responsive drug release, cuproptosis interpretation, assay controls, and mechanistic validation.
-
AM 281: CB1 Cannabinoid Receptor Antagonist
2026-10-01
AM 281 enables selective interrogation of CB1 signaling in receptor, astrocyte, and traumatic brain injury workflows. Its strongest use-case is mechanistic neuropharmacology: connecting CB1 activity with CREB phosphorylation, GLT-1 regulation, glutamate excitotoxicity, and cognitive outcomes.
-
DLL3 Research Strategy: From Detection to Translation
2026-09-30
A translational framework for using the Anti-DLL3 Antibody (Dragonfly patent anti-DLL3) to connect DLL3 protein detection, mechanistic studies, and preclinical evaluation with emerging transient DLL3-directed CAR-T strategies in small cell lung cancer.
-
Cyclic di-GMP, HipH, and Biofilm Persistence
2026-09-30
Liao and colleagues identify cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during early biofilm development. Their results connect adhesion-stage signaling with DNA double-strand breaks, genome instability, and antibiotic persistence, providing a mechanistic framework for biofilm resilience beyond simple nutrient limitation or diffusion models.
-
AM 281: CB1 Antagonist Research Guide
2026-09-29
AM 281 is a potent CB1 cannabinoid receptor antagonist and inverse agonist with nanomolar CB1 affinity. Its reported ability to reverse CB1–CREB–GLT-1 changes after traumatic brain injury makes it a useful tool for memory impairment research, while its selectivity and solubility impose important experimental limits.
-
DNase I (RNase-free): Translational Precision
2026-09-29
A mechanistic and strategic guide to using DNase I (RNase-free) for DNA removal in RNA extraction, RT-PCR, in vitro transcription, and chromatin workflows while protecting experimental interpretability.
-
BMX-IN-1: From Phosphosite to Host-Directed Assays
2026-09-28
BMX-IN-1 is a selective BMX kinase inhibitor that connects covalent target engagement with lysosomal, infection, and cancer-cell phenotypes. This article presents a phosphosite-to-phenotype framework for designing better BMX assays and interpreting results in tuberculosis and oncology research.
-
Bleeding Risk During Extended VTE Anticoagulation
2026-09-28
A prospective multinational cohort study assessed bleeding risk during extended anticoagulation after unprovoked or weakly provoked venous thromboembolism. Modified ACCP, VTE-BLEED, and HAS-BLED scores separated higher-risk from lower-risk patients, while the simpler CHAP model offered a promising approach that still requires external validation.
-
How Simvastatin Modulates Phospholipid Bilayers
2026-09-27
All-atom molecular dynamics simulations compared simvastatin’s inactive lactone and active acid forms in phospholipid membranes, revealing distinct membrane locations and composition-dependent effects on bilayer behavior. The findings provide a molecular-scale framework for studying statin–membrane interactions, but do not establish a direct cause of statin-associated muscle symptoms.
-
GLT-1–CB1–CREB Signaling After TBI
2026-09-26
A 2025 mouse study links post-traumatic 2-AG signaling to reduced astrocytic GLT-1 through CB1-dependent suppression of CREB phosphorylation. Pharmacological CB1 blockade restored GLT-1-associated protection, reduced neuronal apoptosis, and improved behavioral measures, identifying a pathway for further investigation rather than establishing a treatment for human TBI.